Search clinical trials for: SHR-1314 Phase 1

Total 61037 results

Pierre Fabre Pharma GmbH
Pierre Fabre Pharma Austria; Pierre Fabre Pharma AG

Recruiting

Binimetinib Plus Encorafenib Real Life Investigation of Next Generation Melanoma Treatment (BERING)

Melanoma Stage IV | Melanoma Stage III

Austria, Germany, Switzerland
EA Pharma Co., Ltd.

Completed

A Study of E6011 in Participants With Active Crohn's Disease

Crohn's Disease

Czechia, Hungary, Japan, Poland, Russian Federation
Pierre Fabre Pharma AG

Completed

Real Life Study on Iron Isomaltoside 1000 in the Treatment of ID in CKD, Heart Failure, ObGyn, IBD, Cancer and Elective Surgery (Real-CHOICE). (Real-CHOICE)

Iron-Deficiency Anemia | Iron-Deficiency

Switzerland
InDex Pharmaceuticals

Completed

The Efficacy of Cobitolimod in Patients With Moderate to Severe Active Ulcerative Colitis (CONDUCT)

Ulcerative Colitis

Hungary, Czechia, France, Germany, Poland, Russian Federation, Serbia, Spain, Sweden, Ukraine
UCB Japan Co. Ltd.

Completed

A Trial to Evaluate the Long Term Safety and Tolerability of Lacosamide Taken as Monotherapy in Adults With Partial-onset Seizures

Epilepsy | Partial-onset Seizures

Japan
UCB Biopharma S.P.R.L.
Parexel

Completed

A Study to Assess the Effectiveness of Certolizumab Pegol in Patients With Axial Spondyloarthritis in Daily Life (CIMAX)

Axial Spondyloarthritis

Belgium, Germany, Greece, Italy, Spain, United Kingdom
UCB Japan Co. Ltd.

Completed

A Double-blind, Placebo-controlled Study of Levetiracetam in Epilepsy Patients With Generalized Tonic-clonic Seizures (Except Partial Seizures Evolving to Secondarily Generalized Seizures)

Epilepsy | Generalized Tonic-Clonic Seizures

China, Japan
UCB Pharma

Completed

A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-naïve Adults With Early Active Rheumatoid Arthritis (C-early)

Rheumatoid Arthritis

Germany, United States, Argentina, Australia, Austria, Belgium, Canada, Colombia, Czechia, France, Hungary, Ireland, Italy, Mexico, Monaco, Netherlands, Poland, Romania, Spain, Sweden, Switzerland, United Kingdom
UCB BIOSCIENCES, Inc.
PRA Health Sciences

Terminated

Efficacy Evaluation of Intravenous Brivaracetam and Phenytoin in Subjects With Nonconvulsive Electrographic Seizures

Nonconvulsive Electrographic Seizures

United States
UCB Pharma GmbH

Completed

Observational Study With Neupro® to Evaluate the Patient´s Perception of Pain Associated With Parkinson´s Disease (NEUPAD)

Idiopathic Parkinson's Disease

Germany, Austria
UCB Korea Co., Ltd.

Completed

Levetiracetam Versus Topiramate as Adjunctive Therapy to Evaluate Efficacy and Safety in Subjects With Refractory Partial Onset Seizures

Epilepsy

Korea, Republic of
UCB Pharma

Completed

Open Label Extension Study of Epratuzumab in Japanese Systemic Lupus Erythematosus (SLE) Subjects

Systemic Lupus Erythematosus

Japan
UCB Japan Co. Ltd.

Completed

An Open Label Study of Levetiracetam Monotherapy in Patients With Newly Diagnosed Focal Epilepsy

Epilepsy | Partial Onset Seizures

Japan
UCB Celltech

Completed

A Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of UCB4940 in Patients With Psoriasis

Mild to Moderate Psoriasis

United Kingdom
UCB Celltech
Parexel

Completed

Study to Assess the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Profiles of UCB5857 in Healthy Subjects

Healthy Volunteers

United Kingdom
UCB Pharma GmbH

Completed

Vimpat® Added as Adjunctive Therapy to One Baseline Antiepileptic Drug (VITOBA)

Epilepsies, Partial

Germany
UCB Pharma SA

Completed

Comparison of Brivaracetam Oral Tablet (10 mg, 50 mg, 75 mg and 100 mg) and Brivaracetam Injection (100 mg) in Healthy Volunteers

Healthy Volunteers

Netherlands
UCB Japan Co. Ltd.

Completed

An Open Label Study of L059 Intravenous (IV) in Japanese Epilepsy Subjects With Partial Onset Seizures

Epilepsy | Partial Onset Seizures

Japan
UCB Pharma

Completed

Safety Study of CDP7657 in Healthy Volunteers and Patients With Systemic Lupus Erythematosus (SLE)

Immune System Diseases | Autoimmune Diseases | Lupus Erythematosus, Systemic | Skin and Connective Tissue Diseases | Connective Tissue Disease

Belgium, Bulgaria, Germany
UCB Pharma

Completed

An Open-label, Bioequivalence Study to Evaluate LEV Administered as a 45-min Intravenous Infusion and Same Dosage LEV Oral Tablet in Chinese

Human Volunteers

China
UCB Pharma
Otsuka Pharmaceutical Co., Ltd.

Completed

Bioequivalence Study of Rotigotine Transdermal Patch With Two Different Formulations in Healthy Japanese Subjects

Healthy Volunteers

Germany
Sichuan Cancer Hospital and Research Institute
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Apatinib Combined With SHR-1210 Injection in the Treatment of Patients With Removable IB-IIIA NSCLC

Neoplasms | Respiratory Tract Diseases | Lung Diseases | Thoracic Neoplasms | Non-small-cell Lung Cancer

China
Shanghai Hengrui Pharmaceutical Co., Ltd.

Recruiting

A Trial of SHR-1905 in Healthy Subjects and Subjects With Mild Asthma

Asthma

China
Shanghai Hengrui Pharmaceutical Co., Ltd.

Enrolling by invitation

A Study to Extend Efficacy and Safety of SHR-1819 Injection in Adult Patients With Moderate to Severe Atopic Dermatitis

Moderate to Severe Atopic Dermatitis

China
Fudan University

Recruiting

Anti-PD-1 Antibody in the Treatment of Patients With Malignant Melanoma of the Female Genital Tract

Malignant Melanoma

China
Henan Cancer Hospital

Not yet recruiting

Clinical Study of SHR-A1921 or SHR-A2009 in Previously Treated Advanced NSCLC

NSCLC

China
Cancer Institute and Hospital, Chinese Academy...

Recruiting

SHR-A1811 in Combination With Adebrelimab for the Treatment of HER2 Low-expressing Metastatic Breast Cancer

Breast Cancer

China
Shanghai Zhongshan Hospital
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Neoadjuvant Chemoradiation Plus PD-1 Antibody(SHR-1210) in Locally Advanced Proximal Stomach Adenocarcinoma (Neo-PLANET)

Gastric Adenocarcinoma

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Study of SHR-1802 in Patients With Advanced Solid Tumor

Advanced Solid Tumor

China
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Not yet recruiting

Clinical Study of SHR-A1921 Combined With Adebrelimab and SHR-8068 With or Without Carboplatin in the Treatment of Advanced NSCLC

Advanced Non-small Cell Lung Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Not yet recruiting

Phase Ib/II Study of Almonertinib Combined With SHR-1701 in the Treatment of Relapsed or Advanced Non-small Cell Lung Cancer

Relapsed or Advanced Non-small Cell Lung Cancer
Guangdong Hengrui Pharmaceutical Co., Ltd

Recruiting

A Study to Evaluate the Efficacy and Safety of SHR-1703 in Subjects With Eosinophilic Granulomatosis With Polyangiitis （EGPA）

Eosinophilic Granulomatosis With Polyangiitis

China
Beijing Suncadia Pharmaceuticals Co., Ltd

Active, not recruiting

Safety and Tolerability of SHR-1918 in Healthy Subjects

Hyperlipemia

China
Jiangsu HengRui Medicine Co., Ltd.

Withdrawn

A Trial of SHR-1701 With or Without Famitinib in Patients With Advanced or Metastatic NSCLC

Non-Small-Cell Lung Cancer
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Study of SHR-1501 Combined With SHR-1316 in Patients With Advanced Tumors

Advanced Malignancies

Australia, China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Phase Ib/II Study of SHR-A1811 Injection in Breast Cancer

Breast Cancer

China
Shanghai Hengrui Pharmaceutical Co., Ltd.

Recruiting

Safety and Pharmacodynamics of SHR-1707 in Alzheimer's Disease Patients

Alzheimer's Disease

China
Guangdong Hengrui Pharmaceutical Co., Ltd

Recruiting

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SHR-3032 in Healthy Subjects

Prevention of Graft Rejection After Organ Transplantation

China
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Enrolling by invitation

A Trial of the Combination of SHR-A1811 and Fluzoparib in HER2-Expressing Cancers

Advanced Solid Tumors

China
Adocia

Completed

A Double-blinded, Randomised, Three-period Crossover Euglycaemic Clamp Trial Investigating the Pharmacokinetics, Glucodynamics and Safety of BioChaperone Human Insulin, Human Insulin (Huminsulin® Normal) and Insulin Lispro (Humalog®) in Subjects With Type 1 Diabetes

Diabetes Mellitus Type 1

Germany
Shanghai Hengrui Pharmaceutical Co., Ltd.

Recruiting

Safety, Tolerability and Pharmacodynamics of SHR-1707 in Alzheimer's Disease Patients.

Alzheimer's Disease

China
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

A Study to Evaluate the Pharmacodynamic, Efficacy and Safety of SHR-1703 in Asthma Patients With Eosinophil Phenotype

Asthma With Eosinophilic Phenotype

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

Study of SHR-1209 in the Treatment of Hypercholesterolemia and Hyperlipidemia Ⅲ Stage

Primary Hypercholesterolemia | Mixed Hyperlipemia

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

SHR - 1209 Treatment Efficacy and Safety of the Patients With Hypercholesterolemia Ⅲ Period Clinical Research

Primary Hypercholesterolemia

China
The First Affiliated Hospital of Zhengzhou University

Not yet recruiting

Study of Anti-PD-1 Antibody SHR-1210 Plus Nimotuzumab in the Treatment of Advanced Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

China
Atridia Pty Ltd.

Recruiting

A Trial of SHR-1707 Infusion in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease

Alzheimer's Disease (AD)

Australia
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Recruiting

A Study of SHR-4602 in Subjects With Advanced Malignant Solid Tumors

Advanced Solid Tumor

China
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

Phase II Clinical Study of SHR-A1811 in Patients With HER2 Expression / Amplification of Locally Advanced Unresectable or Recurrent Metastatic Biliary Tract Cancer

HER2 Expression / Amplification in Patients With Biliary Tract Cancer

China
Shanghai Hengrui Pharmaceutical Co., Ltd.

Recruiting

A Phase I Clinical Study of SHR-2005 Intravesical Instillation in the Treatment of High-risk Non-muscle Invasive Bladder Cancer (NMIBC)

High-risk Non-muscle Invasive Bladder Cancer

China
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Recruiting

An Open Phase I Clinical Trial of SHR-1826 for Injection in Patients With Advanced Solid Tumors

Advanced Solid Tumors

China

3

Subscribe